Yes you are right about the wounds business, but I believe that it is a formalisation of a collobaration with RAH which will be moved into a separate company but not necessarily an IPO. To give it some autonomy to advance the research.
XBL since the AGM preso has talked about IPO's to realise value. Poly Novo obvious chioice, while trade sale for Boron is a possibility.
Selling drying up.
XBL
xceed biotechnology ltd
